Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The Journal of biological chemistry , 289 (28), 1950819518
Continuous GLP-1RA use for three years was associated with the greatest reduction in MACE risk compared with sulfonylureas, whereas interruptions and discontinuations were associated with a progressive attenuation of this protective effect, with risk estimates in some scenarios approaching those of the comparator group
No prescription or shipment test was completed
Product Details Product Name: PT-141 Form: Lyophilized powder Purity: 99% (HPLC verified) Packaging: Sterile sealed vial Storage: Store in a cool, dry place Intended Use: For laboratory research use only Notice: This material is supplied strictly for research purposes only
Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias
